BioPharma Resources

Drug Trial Radar · NCT07935369

RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma

A Randomized, Controlled, Open-Label, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of RC118 in Combination With RC148 Versus PD-1 Inhibitor Plus Chemotherapy as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Apr 30, 2030

Study completion Dec 31, 2031

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter Phase II/III study evaluating the efficacy and safety of RC118 (an antibody-drug conjugate targeting Claudin 18.2) in combination with RC148 versus PD-1 inhibitor (Tislelizumab) plus chemotherapy (CAPOX) as first-line treatment in patients with Claudin 18.2-positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The study consists of two phases: Phase II will explore the optimal dose combination of RC118 and RC148 across three experimental arms versus a standard comparator arm. Phase III will evaluate the efficacy (progression-free survival) of the recommended Phase III dose (RP3D) combination versus standard of care.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • RC118(Dose 1) plus RC148(Dose 1)Drug

    Dose1+Dose1

  • RC118(Dose 1) plus RC148(Dose 2)Drug

    Dose1+Dose2

  • RC118(Dose 2) plus RC148(Dose 1)Drug

    Dose2+Dose1

  • Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine TabletsDrug

    Tislelizumab (200 mg Q3W) + Oxaliplatin (130 mg/m² Q3W, max 6 cycles) + Capecitabine (1000 mg/m² BID, D1-14 Q3W)

  • RC118 plus RC148 (phase III)Drug

    The dose for Phase III will be determined based on Phase II results.

  • Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)Drug

    Tislelizumab (200 mg Q3W) + Oxaliplatin (130 mg/m² Q3W, max 6 cycles) + Capecitabine (1000 mg/m² BID, D1-14 Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (phase II)Objective Response Rate assessed by the investigators according to RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months.
  2. (phase III)Progression-Free Survival assessed by the BIRC according to RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.